Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events.

Hiroki Wakabayashi,Hitoshi Inada,Yosuke Nishioka,Masahiro Hasegawa,Kusuki Nishioka,Akihiro Sudo

Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events.

2017

Hiroki Wakabayashi
Hitoshi Inada
Yosuke Nishioka
Masahiro Hasegawa
Kusuki Nishioka
Akihiro Sudo

Background Some rheumatoid arthritis (RA) patients initially respond to treatment with infliximab (IFX), but subsequently their responsiveness decreases.

Keywords:

Diabetes mellitus
Infliximab
Rheumatoid arthritis
Medicine
Disease
Golimumab
Physical therapy
Adverse effect
disease activity
in patient
Pharmacology
Pharmacotherapy
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations